Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Revenue Growth %: -7.0%
Financial Fact:
Income from continuing operations before income taxes: 4M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.40, $0.01 better than the analyst estimate of $0.39. Revenue for the quarter came in at $180 million versus the consensus estimate of $183.3 million.
Myriad Genetics sees FY2015 EPS of $1.44-$1.46, versus prior guidance of $1.50-$1.55 and the consensus of $1.52. Myriad Genetics sees FY2015 revenue of $720-722 million, versus prior guidance of $730-740 million and the consensus of $734.19 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Liberty Oilfield Services (LBRT) Misses Q3 EPS by 1c
- Packaging Corp. (PKG) Tops Q3 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
